Abstracts tagged "osteoporosis"

Abstract Number: 1719 • ACR Convergence 2023
Exploring the Link Between Osteitis and Bone Microstructure Changes in Rheumatoid Arthritis: Role of JAK-STAT Signaling Pathway
Tsuneyasu Yoshida¹, Yoichi Nakayama¹, Masao Katsushima², Yuri Nishida³, Mirei Shirakashi¹, Ran Nakashima¹, Ryu Watanabe², Kosaku Murakami⁴, Hajime Yoshifuji¹, Akio Morinobu¹ and Motomu Hashimoto², ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Department of Clinical Immunology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan, ³Department of Endocrinology and Rheumatology, Kurashiki Central Hospital, Kurashiki, Japan, ⁴Center for Cancer Immunotherapy and Immunobiology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Background/Purpose: Osteitis on MRI and bone microstructure changes (BMC) on high-resolution peripheral quantitative CT are the earliest signs of arthritis, preceding the development of bone…
Abstract Number: 2010 • ACR Convergence 2023
B-FROST: Chronic OBstructive Pulmonary Disease and Vertebral FRacture of OSTeoporotic Origin: Results of a Real-life Cohort
Amine Mouamnia, Armentieres Hospital Center, Armentieres, France
Background/Purpose: Chronic obstructive pulmonary disease (COPD) is a chronic disease of the airways. It is mainly caused by smoking. Active smoking is a risk factor…
Abstract Number: 2531 • ACR Convergence 2023
Proton Pump Inhibitor Use Is Associated with Impaired Bone Mineral Density but Not Bone Microarchitecture in Patients with Inflammatory Rheumatic and Musculoskeletal Diseases Taking Glucocorticoids
Andriko Palmowski¹, Gabriela Schmajuk², Jinoos Yazdany³, Patti Katz⁴, Jing Li⁵, Rachael Stovall⁵, Emma Kersey⁵, Sabrina Mai Nielsen⁶, Robin Christensen⁷, Henning Bliddal⁸, Zhivana Boyadzhieva⁹, Udo Schneider⁹, Tobias Alexander¹⁰, Burkhard Muche¹¹, Sandra Hermann¹¹, Edgar Wiebe¹¹ and Frank Buttgereit¹¹, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²UCSF / SFVA, San Francisco, CA, ³University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁴University of California San Francisco, San Rafael, CA, ⁵University of California San Francisco, San Francisco, CA, ⁶The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, ⁷Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, ⁸The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark, ⁹Charité Universitatsmedizine - Berlin, Berlin, Germany, ¹⁰Charité Universiätsmedizin Berlin, Dept. Rheumatology, Berlin, Germany, ¹¹Charité Universitätsmedizin, Dept. Rheumatology, Berlin, Germany
Background/Purpose: Patients with inflammatory rheumatic and musculoskeletal diseases (iRMDs) are at increased risk of osteoporosis and fragility fractures. For this population, whether proton pump inhibitor…
Abstract Number: 1818 • ACR Convergence 2023
Compliance with Romosozumab and Fracture Risk Among Postmenopausal Women in the U.S
Ye Liu¹, Tarun Arora², Jeffrey Curtis¹ and Jingyi Zhang¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Foundation for Advancing Science, Technology, Education, and Research, Birmingham, AL
Background/Purpose: Romosozumab (romo) is a newly approved osteoporosis (OP) medicine for women with postmenopausal OP at high risk of fracture. The utilization pattern of romo…
Abstract Number: 2011 • ACR Convergence 2023
Predicting Fractures in Patients with Isolated Lumbar Spine Osteoporosis Compared to Those with Isolated Hip Osteoporosis
Nicholas Rossi¹, Aamir Saeed², Aqib Khan³, Hamzah Amin², Ummaz Nadeem², Zain Sultan³ and Marwan Bukhari², ¹University Hospitals of Morecambe Bay Foundation Trust, Worksop, United Kingdom, ²Lancaster University, Lancaster, United Kingdom, ³University Hospitals of Morecambe Bay Foundation Trust, Lancaster, United Kingdom
Background/Purpose: Osteoporosis (OP) presents with fragility fractures, which can cause significant disability and cost to health services globally. There has been extensive research looking at…
Abstract Number: 2532 • ACR Convergence 2023
Prevalence and Disease-Specific Factors Associated with Osteoporosis in Systemic Sclerosis: A Cross-Sectional Analysis of Two Large European Cohorts
Charles MIDOL¹, Edgar Wiebe², Elise Siegert³, Dörte Huscher⁴, Helene Behal⁵, David Launay⁶, Eric Hachulla⁷, Eric Matteson⁸, Vincent Sobanski⁹ and Frank Buttgereit², ¹Lille University Hospital, Besançon, France, ²Charité Universitätsmedizin, Dept. Rheumatology, Berlin, Germany, ³Department of Rheumatology, Charité University Hospital, Charité Platz 1, D-10117, Berlin, Germany, ⁴Institute of Biometry and Clinical Epidemiology and Berlin Institute of Health, Charité Universitätsmedizin Berlin, Berlin, Germany, ⁵Univ. Lille, CHU Lille, Biostatistics Department, Lille, France, ⁶Univ. Lille, Inserm, CHU Lille, Service de Médecine Interne, Lille, France, ⁷CHU Lille, Département de Médecine Interne et Immunologie Clinique, Centre de Référence des Maladies Auto-immunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), Lille, France, ⁸Mayo Clinic College of Medicine and Science, Rochester, MN, USA, Rochester, MN, ⁹Univ. Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, Lille, France
Background/Purpose: Patients with systemic sclerosis (SSc) are at increased risk for osteoporosis (OP) and associated fragility fractures. However, the risks factors and mechanisms driving bone…
Abstract Number: 1867 • ACR Convergence 2023
Peripheral Volumetric Bone Mineral Density and Erosive Disease in Patients with Established Rheumatoid Arthritis: A Cross-Sectional Study Using High-Resolution Peripheral Quantitative Computed Tomography
Mathias Hänel¹, Rasmus Klose-Jensen², Josephine Therkildsen³, Anne-Birgitte Garm Blavnsfeldt³, Bente Langdahl³, Stinus Gadegaard Hansen⁴, Kresten Keller⁵ and Ellen Margrethe Hauge³, ¹Rheumatollogy, Aarhus University Hospital, Aarhus, Denmark, ²Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Aarhus University Hospital, Aarhus, Denmark, ⁴Odense University Hospital, Svendborg Sygehus, Svendborg, Denmark, ⁵Department of Rheumatology, Aarhus University Hospital; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
Background/Purpose: High resolution peripheral quantitative computed tomography (HR-pQCT) is a promising imaging modality for assessing volumetric bone mineral density (BMD) in rheumatoid arthritis (RA), and…
Abstract Number: 2012 • ACR Convergence 2023
Incidence of Hyperparathyroidism in Patients with Osteoporosis Treated with Zoledronic Acid or Denosumab
Carmen Riesco Barcena¹, Jose Ivorra Cortes², Elena Grau Garcia², Samuel Leal Rodriguez², Luis Gonzalez Puig², Anderson Victor Huaylla Quispe², Pablo Francisco Muñoz Martínez³, Alba Maria Torrat Noves², Daniel Ramos Castro², Laura Mas Sanchez⁴, Ines Canovas Olmos², Hikmat Charia², Isabel Martinez Cordellat², Carmen Najera Herranz², Rosa Negueroles Albuixech², Jose Eloy Oller Rodriguez², Marta De la Rubia Navarro⁴, Ernesto Tovar Sugrañes², Elvira Vicens Bernabeu², Iago Alcantara Alvarez², Belen Villanueva Mañez² and Jose Andres Roman Ivorra⁵, ¹Hospital Universitario y Politécnico La Fe, Valencia, Spain, ²Rheumatology Department. HUP La Fe, Valencia, Spain, ³Rheumatology Department. HUP La Fe, Sagunto, Spain, ⁴Rheumatology Department. HUP La Fe, Valéncia, Spain, ⁵Hospital Universitari i Politècnic la Fe, Valencia, Spain
Background/Purpose: Denosumab and Zoledronic acid are antiresorptive drugs commonly used in the treatment of osteoporosis (OP). Zoledronic acid is a third-generation bisphosphonate that inhibits osteoclastic…
Abstract Number: 1996 • ACR Convergence 2023
Variation in Dual-energy X-ray Absorptiometry Reporting: A National Survey of Veterans Health Administration Clinics
Karla Miller¹, Melissa Steffen², Kimberly McCoy², Michelle Mengeling², Heather Davila², Shylo Wardyn² and Samantha Solimeo², ¹University of Utah School of Medicine, Salt Lake City, UT, ²Department of Veterans Affairs, Iowa City VA HCS, Iowa City, IA
Background/Purpose: Dual-energy x-ray absorptiometry (DXA) is an important tool to identify Veterans with osteoporosis, assess fracture risk, and monitor treatment response. Variability in DXA acquisition,…
Abstract Number: 2013 • ACR Convergence 2023
Clinical Characteristics and Risk Factors Associated with Fragility Fractures in Patients with Primary and Idiopathic Mast Cell Activation Syndromes
Ana Isabel Ramos Lisbona¹, Karen Carpio Astudillo¹, Filip Skrabski¹, Alicia Prieto García¹, Isabel Castrejon¹, Javier Rivera², José María Álvaro-Gracia¹ and Teresa González¹, ¹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Hospital General Universitario Gregorio Marañon, Madrid, Spain
Background/Purpose: Mast Cell Activation Syndromes (MCAS) are a group of disorders presenting with episodic multisystem symptoms, predominantly anaphylaxis, as the result of mast cell mediator…
Abstract Number: 1998 • ACR Convergence 2023
How to Tailor Osteoporosis Therapies in Patients with Advanced Liver Disease? Variations of Renal Function by Creatinine and Cystatin C
Cristina Rodríguez-Alvear¹, Mª Carmen López-González², Elisabet Perea-Martínez³, Antonio Avilés-Hernández³, Eduardo Garín Cascales³, Nuria Buendía Sánchez³, Irene Calabuig-Sais¹, Pilar Bernabeu-Gonzálvez³, Agustín Martínez-Sanchís¹, Joaquim Esteve-Vives³, PALOMA VELA⁴, Cayetano Miralles Maciá³, Vega Jovani⁵ and Mariano Andrés¹, ¹Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain, ²General University Hospital Dr. Balmis, Alacante, Spain, ³General University Hospital Dr. Balmis, Alicante, Spain, ⁴Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ⁵Department of Rheumatology, Hospital General Universitario Dr. Balmis, Alicante, Spain
Background/Purpose: Rapid bone loss and increased fractures have been described after liver transplantation. Bisphosphonates are restricted in patients with significant kidney disease, as the drugs…
Abstract Number: 2014 • ACR Convergence 2023
The Role of Orosomucoid 2 in the Regulation of Bone Remodeling by Inhibiting Osteoclastogenesis and Promoting Osteogenesis
CHONG HYUK CHUNG¹, Myeung-Su Lee¹ and Chang-hoon Lee², ¹Wonkwang University Hospital, Iksan, South Korea, ²Wonkwang University Hospital, Iksan Jeonbuk, South Korea
Background/Purpose: Orosomucoid (ORM) is one of the acute phase reactant protein family and is expressed in hepatocytes and secreted into plasma under stress conditions such…
Abstract Number: 1999 • ACR Convergence 2023
One-year Incidence of Clinical Fragility Fractures After Implementing an Osteoporosis Care Protocol in Patients Eligible for Liver Transplantation
Cristina Rodríguez-Alvear¹, Mª Carmen López-González², Elisabet Perea-Martínez³, Antonio Avilés-Hernández³, Irene Calabuig-Sais¹, Maria-Luisa Peral-Garrido⁴, Pilar Bernabeu-Gonzálvez³, Agustín Martínez-Sanchís¹, Joaquim Esteve-Vives³, PALOMA VELA⁵, Cayetano Miralles Maciá³, Vega Jovani⁶ and Mariano Andrés¹, ¹Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain, ²General University Hospital Dr. Balmis, Alacante, Spain, ³General University Hospital Dr. Balmis, Alicante, Spain, ⁴Vinalopó University Hospital, Novelda, Spain, ⁵Rheumatology, Hospital General Universitario Alicante, Alicante, Spain, ⁶Department of Rheumatology, Hospital General Universitario Dr. Balmis, Alicante, Spain
Background/Purpose: In solid organ transplantation, liver transplants are among those most frequently associated with the development of low bone mass, which occurs in up to…
Abstract Number: 2016 • ACR Convergence 2023
Generation of a Human 3D in Vitro Bone Model That Mimics Glucocorticoid-induced Osteoporosis
Moritz Pfeiffenberger¹, Johannes Plank¹, Alexandra Damerau¹, Timo Gaber¹ and Frank Buttgereit², ¹Charité Universitatsmedizine - Berlin, Berlin, Germany, ²Charité Universitätsmedizin, Dept. Rheumatology, Berlin, Germany
Background/Purpose: Osteoporosis is a bone disease characterized by low bone mass and changes in bone architecture, leading to pain and reduced mobility in patients. Glucocorticoid-induced…
Abstract Number: 2000 • ACR Convergence 2023
Efficacy of Romosozumab for Glucocorticoid-induced Osteoporosis in Patients with Rheumatic Diseases; A Prospective Study
Mai Kawazoe¹, Kaichi Kaneko², Shotaro Masuoka³, Soichi yamada³, Zento Yamada³, Sei Muraoka³, Karin Furukawa¹, Hiroshi Sato³, Eri Watanabe³, Keiko Koshiba³, Izumi Irita³, Miwa Kanaji³ and Toshihiro Nanki¹, ¹Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Ota-ku, Japan, ²Division of Rheumatology, Department of Internal Medicine, Toho University Sakura Medical Center, Sakura, Japan, ³Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine, Tokyo, Japan
Background/Purpose: Glucocorticoids are widely used to treat a variety of diseases, including rheumatic diseases. Although glucocorticoids improve the outcome for these diseases, various side effects…

« Previous Page
1
…
3
4
5
6
7
…
20
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].